NCT04711434View on ClinicalTrials.gov

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

PHASE3RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Lynch Syndrome
Interventions
DRUG

PD-1 Antibody

Toripalimab: 240mg IV every 3 months for a year

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University, Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

collaborator

Fujian Cancer Hospital

OTHER_GOV

collaborator

Guangdong Provincial People's Hospital

OTHER

collaborator

Guangdong Provincial Hospital of Traditional Chinese Medicine

OTHER

collaborator

The Third Affiliated Hospital of Kunming Medical College.

OTHER

lead

Sun Yat-sen University

OTHER